ADARx Pharmaceuticals
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, ADARx Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
ADARx Pharmaceuticals: 4 sponsored US clinical trials, 4 recruiting.
ADARx Pharmaceuticals sponsors 4 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting. 2 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hereditary Angioedema - Type 2, with 1 trials.
Upper-quartile sponsor footprint
ADARx Pharmaceuticals sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 2 |
What is open in the ADARx Pharmaceuticals pipeline
4 recruiting of 4 indexed (100% open).
Phase mix: 2 late (III/IV) vs 2 early (I/II) (balanced across stages).
Top condition: Hereditary Angioedema - Type 2 (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
ADARx Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 4 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
ADARx Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- Adcendo ApS · 100% recruiting · 3 trials
Related
What to do with this ADARx Pharmaceuticals page
4 registered trials is a research-attention snapshot, not an endorsement of ADARx Pharmaceuticals or any single study.
- 4 of ADARx Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hereditary Angioedema - Type 2 is the condition ADARx Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hereditary Angioedema - Type 2 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
ADARx Pharmaceuticals pipeline card: 4 registered trials from official public datasets.Report a data error.